Rite Aid brings EQuIPP platform to all its pharmacies
CAMP HILL, Pa. — Rite Aid on Wednesday announced that all of the company’s pharmacists in its almost 4,600 stores have started using Pharmacy Quality Solutions’ EQuIPP platform to access performance data and metrics. Rite Aid is the largest chain to use EQuIPP for its pharmacists.
“Value-based healthcare is here to stay and that’s why it’s important for Rite Aid to provide our pharmacists with the resources and tools they need to deliver improved health outcomes for their patients,” Rite Aid EVP pharmacy Jocelyn Konrad said. “Our pharmacists are committed to providing excellent care to their customers, and with EQuIPP, we’re empowering them to make an even greater difference in the health and wellbeing of their customers and succeed in today’s healthcare environment.”
The platform allows pharmacists to see data on patient adherence and appropriate medication, as well as compare their performance against benchmarks and look for ways to improve their Star Ratings and outcomes
“We are excited to see Rite Aid provide their pharmacists with EQuIPP access as part of the Company’s continued focus on improving patient outcomes,” PQS VP professional relations Elliott Sogol said. “With an increased value being placed on quality outcomes, having easy access to transparent and accurate performance data is key and will help support Rite Aid’s efforts towards best-in-class quality performance.”
In addition to using EQuIPP, Rite Aid said it has in place various programs aimed at boosting adherence, including medication therapy management and its medication synchronization service One Trip Refill, as well as a compliance monitoring tools and automated courtesy refills.
Takeda announces Ninlaro US availability
BY DSN STAFF
CAMBRIDGE, Mass. — Takeda Pharmaceuticals recently announced the U.S. availability of its Ninlaro (ixazomib), an oral proteasome inhibitor. Ninlaro is indicated to treat patients with multiple myeloma who have received at least one prior therapy. The Food and Drug Administration approved the drug four months ahead of the date of its Priority Review.
“In addition to the clinical investigators and patients, I would like to extend our thanks to the FDA for its expedited review of Ninlaro.” Takeda Oncology president Dr. Christophe Bianchi said. “We are excited to realize our commitment to the multiple myeloma community as we bring Ninlaro to patients.”
Ninlaro, because it is a pill that can be taken at home, could be logistically easier for patients, the company said. Takeda is offering its Ninlaro 1Point support program through Ninlaro.com to help patients with access and coverage questions.
“Access to therapy for patients in need is our first and foremost priority,” Ryan Cohlhepp, Takeda’s VP U.S. marketing, said. “And with NINLARO 1Point, we have created a robust suite of support services to help patients access NINLARO.”
FDA approves Bendeka from Teva, Eagle Pharmaceuticals
JERUSALEM and WOODCLIFF LAKE, N.J. — Teva Pharmaceuticals and Eagle Pharmaceuticals announced Tuesday that the Food and Drug Administration had approved their Bendeka (bendamustine hydrochloride), an injection and 10-minute infusion formulation.
The drug is indicated to treat patients with chronic lymphocytic leukemia and those with indolent B-cell non-Hodgkin lymphoma that’s progressed during or within six months of being treated with rituximab or a regimen with rituximab.
“Teva looks forward to commercializing this new bendamustine product, which we believe represents an important benefit to both patients and healthcare providers,” Teva Oncology general manager and SVP Paul Rittman said. “We are pleased to add BENDEKA to Teva’s Oncology portfolio, and bendamustine franchise, furthering our commitment to enhancing treatment options for patients affected by cancer.”
Teva said it expects to make Bendeka available in the first quarter of 2016.
Loading Post Please Wait...